valproic acid has been researched along with Disease Exacerbation in 59 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Valproic acid (VPA) is an antiepileptic agent with histone deacetylase inhibitor (HDACi) activity shown to sensitize glioblastoma (GBM) cells to radiation in preclinical models." | 9.20 | A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. ( Camphausen, K; Chang, MG; Fine, HA; Holdford, DJ; Krauze, AV; Myrehaug, SD; Shih, J; Smith, S; Tofilon, PJ, 2015) |
| "To determine whether valproic acid (VPA), a histone deacetylase inhibitor that showed antioxidative and antiapoptotic properties and reduced glutamate toxicity in preclinical studies, is safe and effective in amyotrophic lateral sclerosis (ALS) using a sequential trial design." | 9.14 | Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. ( de Jong, JM; de Jong, SW; de Visser, M; Groeneveld, GJ; Piepers, S; Scheffer, H; Schelhaas, HJ; Uijtendaal, EV; van den Berg, LH; van der Pol, WL; van der Tweel, I; Veldink, JH; Wokke, JH, 2009) |
| "Histone deacetylase inhibitors, including valproic acid, selectively induce cellular differentiation and apoptosis in melanoma cells." | 7.96 | Association of Valproic Acid Use, a Potent Histone Deacetylase Inhibitor, and Melanoma Risk. ( Asgari, MM; Chavez, A; Darbinian, J; Quesenberry, CP, 2020) |
| "Valproic acid (VPA) is an antiepileptic agent with histone deacetylase inhibitor (HDACi) activity shown to sensitize glioblastoma (GBM) cells to radiation in preclinical models." | 5.20 | A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma. ( Camphausen, K; Chang, MG; Fine, HA; Holdford, DJ; Krauze, AV; Myrehaug, SD; Shih, J; Smith, S; Tofilon, PJ, 2015) |
| "To determine whether valproic acid (VPA), a histone deacetylase inhibitor that showed antioxidative and antiapoptotic properties and reduced glutamate toxicity in preclinical studies, is safe and effective in amyotrophic lateral sclerosis (ALS) using a sequential trial design." | 5.14 | Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. ( de Jong, JM; de Jong, SW; de Visser, M; Groeneveld, GJ; Piepers, S; Scheffer, H; Schelhaas, HJ; Uijtendaal, EV; van den Berg, LH; van der Pol, WL; van der Tweel, I; Veldink, JH; Wokke, JH, 2009) |
| " We describe the phenomenon of amygdala-kindled seizures episodically breaking through effective daily pharmacotherapy with carbamazepine and valproate, suggesting that these observations could reflect the balance of pathological vs compensatory illness-induced changes in gene expression." | 4.79 | A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. ( Post, RM; Weiss, SR, 1996) |
| "Histone deacetylase inhibitors, including valproic acid, selectively induce cellular differentiation and apoptosis in melanoma cells." | 3.96 | Association of Valproic Acid Use, a Potent Histone Deacetylase Inhibitor, and Melanoma Risk. ( Asgari, MM; Chavez, A; Darbinian, J; Quesenberry, CP, 2020) |
| " Because a high fat low carbohydrate ketogenic diet (KD) augments adenosine signaling in the brain and because adenosine not only suppresses seizures but also affects epileptogenesis, we hypothesized that a ketogenic diet might prevent epileptogenesis through similar mechanisms." | 3.81 | Ketogenic diet prevents epileptogenesis and disease progression in adult mice and rats. ( Akula, KK; Boison, D; Coffman, SQ; Lusardi, TA; Masino, SA; Ruskin, DN, 2015) |
| "Valproic acid (VPA) reduces latent human immunodeficiency virus (HIV) reservoirs by activating resting CD4+ cells." | 3.73 | Valproic acid does not affect markers of human immunodeficiency virus disease progression. ( Ances, BM; Buzzell, M; Ellis, RJ; Grant, I; Lazaretto, D; Letendre, S; Marcotte, TD; Marquie-Beck, J, 2006) |
| "Epilepsy was controlled with valproate at the age of 6 years." | 2.42 | A study of EEG and epilepsy profile in Wolf-Hirschhorn syndrome and considerations regarding its correlation with other chromosomal disorders. ( Fiore, LA; Freitas, A; Kim, CA; Valente, KD, 2003) |
| "Progressive myoclonus epilepsy of the Unverricht-Lundborg type is the most common cause of progressive myoclonus epilepsy worldwide." | 2.40 | Clinical features and genetics of progressive myoclonus epilepsy of the Univerricht-Lundborg type. ( Koskiniemi, M; Lehesjoki, AE, 1998) |
| "In a woman with Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) followed for 15 years, we observed magnetic resonance imaging white matter hyperintensities that vanished in the anterior temporal poles while the brain volume decreased unexpectedly." | 1.56 | Vanishing White Matter Hyperintensities in CADASIL: A Case Report with Insight into Disease Mechanisms. ( Alili, N; Chabriat, H; Hervé, D; Jouvent, E, 2020) |
| "Exencephaly/anencephaly is one of the leading causes of neonatal mortality and the most extreme open neural tube defect with no current treatments and limited mechanistic understanding." | 1.51 | Cell necrosis, intrinsic apoptosis and senescence contribute to the progression of exencephaly to anencephaly in a mice model of congenital chranioschisis. ( Duru, S; Fernandez-Alonso, I; Fernandez-Martin, A; Figueira, RL; Marotta, M; Oria, M; Peiro, JL; Sbragia, L; Scorletti, F; Shaaban, AF; Turner, LE, 2019) |
| "Valproic acid has been shown to upregulate estrogen receptors (ERs) in breast and prostate cancer tissues." | 1.48 | Magnesium valproate ameliorates type 1 diabetes and cardiomyopathy in diabetic rats through estrogen receptors. ( Bhadada, S; Dudhrejiya, A; Patel, B; Rabadiya, S; Vaishnav, D, 2018) |
| "Children with Childhood Absence Epilepsy (CAE) may develop generalized tonic-clonic seizure or juvenile myoclonic epilepsy." | 1.48 | Childhood Absence Epilepsy evolving to Eyelid Myoclonia with Absence Epilepsy. ( Fazzi, E; Galli, J; Giordano, L; Malerba, L; Micheletti, S, 2018) |
| "We report five adult patients with frontal lobe epilepsy (FLE) who were treated with VPA and in whom a primary adverse effect was unstable gait and falls." | 1.46 | Gait instability in valproate-treated patients: Call to measure ammonia levels. ( Elger, CE; Kipervasser, S; Korczyn, AD; Nass, RD; Neufeld, MY; Quesada, CM, 2017) |
| "This case reminds us that Sydenham's chorea can result in major functional impairment." | 1.43 | Successful treatment of Sydenham's chorea with intravenous immunoglobulin. ( Boersma, NA; Heidema, J; Kuijpers, T; Schippers, H, 2016) |
| "Multiple generalized seizures occurred in all homozygous mice around three weeks after birth." | 1.42 | Epileptogenesis and epileptic maturation in phosphorylation site-specific SNAP-25 mutant mice. ( Kataoka, M; Miyaoka, H; Otsuka, S; Saito, M; Suzuki, E; Takahashi, M; Watanabe, S; Yamamori, S, 2015) |
| "Benign myoclonic epilepsy in infancy (BMEI) is a well-defined electro-clinical syndrome, classically associated with a good prognosis." | 1.40 | [Benign myoclonic epilepsy in infancy: natural history and behavioral and cognitive outcome]. ( Carreras-Sáez, I; Domínguez-Carral, J; Fournier-Del Castillo, MC; García-Peñas, JJ; Jiménez-Echevarría, S; Pérez-Jiménez, MÁ, 2014) |
| "Malignant migrating partial seizures in infancy (MMPSI) or Coppola-Dulac syndrome is a rare epilepsy syndrome with the onset in the first 6 months of life, characterized by multiple continuous electroencephalographic and electroclinical focal ictal patterns due to the involvement of different independent areas of both hemispheres with the arrest of psychomotor development." | 1.39 | [The syndrome of malignant migrating partial seizures in infancy or Coppola-Dulac syndrome (19 cases)]. ( Kholin, AA, 2013) |
| "Early treatment of epilepsy is warranted to avoid possible severe consequences." | 1.39 | Epilepsy and brain injury: a case report of a dramatic neuropsychiatric vicious circle. ( Angeletti, G; Carbonetti, P; Del Casale, A; Fensore, C; Ferracuti, S; Girardi, P; Kotzalidis, GD; Lazanio, S; Muzi, A; Rapinesi, C; Savoja, V; Scatena, P; Serata, D; Tatarelli, R, 2013) |
| "We describe arginase deficiency in a 20-year-old woman with spastic paraplegia, progressive dystonia, dementia, peripheral neuropathy, epilepsy, liver cirrhosis, and non-B/non-C hepatocellular carcinoma." | 1.38 | Arginase deficiency with new phenotype and a novel mutation: contemporary summary. ( Ching, CK; Fung, CW; Lam, CW; Luk, HM; Mak, CM; Poon, WL; Siu, TS; Tam, S; Tsang, JP; Wong, VC, 2012) |
| "Valproic acid (VA) is a well-tolerated drug used to treat seizure disorders and has recently been shown to inhibit histone deacetylase (HDAC)." | 1.33 | Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. ( Burgan, WE; Camphausen, K; Cerna, D; Cerra, MA; Fine, H; Scott, T; Sproull, M; Tofilon, PJ, 2005) |
| "Using cells and prostate cancer xenograft mouse models, we demonstrate in this study that a combination treatment using the PPARgamma agonist pioglitazone and the histone deacetylase inhibitor valproic acid is more efficient at inhibiting prostate tumor growth than each individual therapy." | 1.33 | Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. ( Abella, A; Annicotte, JS; Berthe, ML; Culine, S; Dubus, P; Fajas, L; Fritz, V; Iankova, I; Iborra, F; Maudelonde, T; Miard, S; Noël, D; Pillon, A; Sarruf, D, 2006) |
| "The myoclonus was worsened by emotion and voluntary activity and was clearly attenuated by sleep." | 1.32 | [Favorable course of Lance-Adams postanoxic action myoclonus]. ( Benabdejlil, M; Benomar, A; Chkili, T; Errguig, L; Messouak, W; Regragui, W; Yahyaoui, M, 2003) |
| "Only several months later, when olfactory hallucinations and alterations in consciousness became evident, was a temporal lobe lesion suspected." | 1.32 | Exacerbation of mania secondary to right temporal lobe astrocytoma in a bipolar patient previously stabilized on valproate. ( Denson, TF; Sokolski, KN, 2003) |
| "Valproic acid (VPA) has long been used as an antiepileptic drug and recently as a mood stabilizer, and evidence is increasing that VPA exerts neuroprotective effects through changes in a variety of intracellular signalling pathways including upregulation of Bcl-2 protein with an antiapoptotic property and inhibiting glycogen synthase kinase 3-beta, which is considered to promote cell survival." | 1.32 | Benefit of valproic acid in suppressing disease progression of ALS model mice. ( Goto, M; Hamasaki, T; Miyaguchi, K; Sakoda, S; Sugai, F; Sumi, H; Yamamoto, Y; Zhou, Z, 2004) |
| "In children with childhood absence epilepsy (CAE) and juvenile absence epilepsy (JAE), to determine the impact of failure of initial antiepileptic drug (AED) for lack of efficacy in eventual seizure control and long-term remission of epilepsy." | 1.31 | Prognostic significance of failure of the initial antiepileptic drug in children with absence epilepsy. ( Camfield, C; Camfield, P; Dooley, J; Wirrell, E, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (8.47) | 18.2507 |
| 2000's | 18 (30.51) | 29.6817 |
| 2010's | 32 (54.24) | 24.3611 |
| 2020's | 4 (6.78) | 2.80 |
| Authors | Studies |
|---|---|
| Oria, M | 1 |
| Duru, S | 1 |
| Figueira, RL | 1 |
| Scorletti, F | 1 |
| Turner, LE | 1 |
| Fernandez-Alonso, I | 1 |
| Fernandez-Martin, A | 1 |
| Marotta, M | 1 |
| Sbragia, L | 1 |
| Shaaban, AF | 1 |
| Peiro, JL | 1 |
| Torres, IJ | 2 |
| Qian, H | 1 |
| Basivireddy, J | 1 |
| Chakrabarty, T | 1 |
| Wong, H | 1 |
| Lam, RW | 2 |
| Yatham, LN | 2 |
| Abulseoud, OA | 1 |
| Şenormancı, G | 1 |
| Şenormancı, Ö | 1 |
| Güçlü, O | 1 |
| Schleyer, B | 1 |
| Camsari, U | 1 |
| Chavez, A | 1 |
| Quesenberry, CP | 1 |
| Darbinian, J | 1 |
| Asgari, MM | 1 |
| Jouvent, E | 1 |
| Alili, N | 1 |
| Hervé, D | 1 |
| Chabriat, H | 1 |
| Martínez-Ferrández, C | 1 |
| Martínez-Salcedo, E | 1 |
| Casas-Fernández, C | 1 |
| Alarcón-Martínez, H | 1 |
| Ibáñez-Micó, S | 1 |
| Domingo-Jiménez, R | 1 |
| Park, S | 1 |
| Hamel, JF | 1 |
| Toma, A | 1 |
| Kelaidi, C | 1 |
| Thépot, S | 1 |
| Campelo, MD | 1 |
| Santini, V | 1 |
| Sekeres, MA | 2 |
| Balleari, E | 1 |
| Kaivers, J | 1 |
| Sapena, R | 1 |
| Götze, K | 1 |
| Müller-Thomas, C | 1 |
| Beyne-Rauzy, O | 1 |
| Stamatoullas, A | 1 |
| Kotsianidis, I | 1 |
| Komrokji, R | 1 |
| Steensma, DP | 1 |
| Fensterl, J | 1 |
| Roboz, GJ | 1 |
| Bernal, T | 1 |
| Ramos, F | 1 |
| Calabuig, M | 1 |
| Guerci-Bresler, A | 1 |
| Bordessoule, D | 1 |
| Cony-Makhoul, P | 1 |
| Cheze, S | 1 |
| Wattel, E | 1 |
| Rose, C | 1 |
| Vey, N | 1 |
| Gioia, D | 1 |
| Ferrero, D | 1 |
| Gaidano, G | 1 |
| Cametti, G | 1 |
| Pane, F | 1 |
| Sanna, A | 1 |
| Germing, U | 1 |
| Sanz, GF | 1 |
| Dreyfus, F | 1 |
| Fenaux, P | 1 |
| Kipervasser, S | 1 |
| Elger, CE | 1 |
| Korczyn, AD | 1 |
| Nass, RD | 1 |
| Quesada, CM | 1 |
| Neufeld, MY | 1 |
| Rabadiya, S | 1 |
| Bhadada, S | 1 |
| Dudhrejiya, A | 1 |
| Vaishnav, D | 1 |
| Patel, B | 1 |
| Cuykx, M | 1 |
| Claes, L | 1 |
| Rodrigues, RM | 1 |
| Vanhaecke, T | 1 |
| Covaci, A | 1 |
| Lv, Y | 1 |
| Zhang, N | 1 |
| Liu, C | 1 |
| Shi, M | 1 |
| Sun, L | 1 |
| Galli, J | 1 |
| Micheletti, S | 1 |
| Malerba, L | 1 |
| Fazzi, E | 1 |
| Giordano, L | 1 |
| Fang, E | 1 |
| Wang, J | 1 |
| Hong, M | 1 |
| Zheng, L | 1 |
| Tong, Q | 1 |
| Huang, Q | 1 |
| Yu, L | 1 |
| Ma, M | 1 |
| Qi, H | 1 |
| Wu, Y | 1 |
| Kholin, AA | 1 |
| Sonmez, FM | 1 |
| Serin, HM | 1 |
| Alver, A | 1 |
| Aliyazicioglu, R | 1 |
| Cansu, A | 1 |
| Can, G | 1 |
| Zaman, D | 1 |
| Kurzrock, R | 1 |
| Atkins, J | 1 |
| Wheler, J | 1 |
| Fu, S | 1 |
| Naing, A | 1 |
| Busaidy, N | 1 |
| Hong, D | 1 |
| Sherman, S | 1 |
| Rapinesi, C | 1 |
| Del Casale, A | 1 |
| Serata, D | 1 |
| Kotzalidis, GD | 1 |
| Scatena, P | 1 |
| Muzi, A | 1 |
| Lazanio, S | 1 |
| Savoja, V | 1 |
| Carbonetti, P | 1 |
| Fensore, C | 1 |
| Ferracuti, S | 1 |
| Angeletti, G | 1 |
| Tatarelli, R | 1 |
| Girardi, P | 1 |
| Domínguez-Carral, J | 1 |
| García-Peñas, JJ | 1 |
| Pérez-Jiménez, MÁ | 1 |
| Fournier-Del Castillo, MC | 1 |
| Carreras-Sáez, I | 1 |
| Jiménez-Echevarría, S | 1 |
| Kozicky, JM | 1 |
| Silveira, LE | 1 |
| Bond, DJ | 1 |
| Kwan, Z | 1 |
| Che Ismail, RB | 1 |
| Wong, SM | 1 |
| Tan, LL | 1 |
| Robinson, S | 1 |
| Lim, KS | 1 |
| Ornstein, MC | 1 |
| Mukherjee, S | 1 |
| Inal-Emiroglu, FN | 1 |
| Resmi, H | 1 |
| Karabay, N | 1 |
| Guleryuz, H | 1 |
| Baykara, B | 1 |
| Cevher, N | 1 |
| Akay, A | 1 |
| Krauze, AV | 1 |
| Myrehaug, SD | 1 |
| Chang, MG | 1 |
| Holdford, DJ | 1 |
| Smith, S | 1 |
| Shih, J | 1 |
| Tofilon, PJ | 2 |
| Fine, HA | 1 |
| Camphausen, K | 2 |
| Watanabe, S | 1 |
| Yamamori, S | 1 |
| Otsuka, S | 1 |
| Saito, M | 1 |
| Suzuki, E | 1 |
| Kataoka, M | 1 |
| Miyaoka, H | 1 |
| Takahashi, M | 1 |
| Lusardi, TA | 1 |
| Akula, KK | 1 |
| Coffman, SQ | 1 |
| Ruskin, DN | 1 |
| Masino, SA | 1 |
| Boison, D | 1 |
| Boersma, NA | 1 |
| Schippers, H | 1 |
| Kuijpers, T | 1 |
| Heidema, J | 1 |
| Carter, CA | 1 |
| Zeman, K | 1 |
| Day, RM | 1 |
| Richard, P | 1 |
| Oronsky, A | 1 |
| Oronsky, N | 1 |
| Lybeck, M | 1 |
| Scicinski, J | 1 |
| Oronsky, B | 1 |
| Johannsen, J | 1 |
| Nickel, M | 1 |
| Schulz, A | 1 |
| Denecke, J | 1 |
| Al-Kzayer, LF | 1 |
| Keizer, P | 1 |
| Abdulraheem, FT | 1 |
| Sano, K | 1 |
| Kamata, M | 1 |
| Sakashita, K | 1 |
| Habbaba, LA | 1 |
| Koike, K | 1 |
| Shan, JC | 1 |
| Hsieh, MH | 1 |
| Liu, CC | 1 |
| Wen, CC | 1 |
| Liu, CM | 1 |
| Zádori, D | 1 |
| Geisz, A | 1 |
| Vámos, E | 1 |
| Vécsei, L | 1 |
| Klivényi, P | 1 |
| Piepers, S | 1 |
| Veldink, JH | 1 |
| de Jong, SW | 1 |
| van der Tweel, I | 1 |
| van der Pol, WL | 2 |
| Uijtendaal, EV | 1 |
| Schelhaas, HJ | 1 |
| Scheffer, H | 1 |
| de Visser, M | 1 |
| de Jong, JM | 1 |
| Wokke, JH | 2 |
| Groeneveld, GJ | 1 |
| van den Berg, LH | 2 |
| Sleegers, MJ | 1 |
| Beutler, JJ | 1 |
| Hardon, WJ | 1 |
| Berden, JH | 1 |
| Verhave, JC | 1 |
| Conemans, JM | 1 |
| Hollander, DA | 1 |
| Dautzenberg, PL | 1 |
| Hoogeveen, EK | 1 |
| Scherpereel, A | 1 |
| Berghmans, T | 1 |
| Lafitte, JJ | 1 |
| Colinet, B | 1 |
| Richez, M | 1 |
| Bonduelle, Y | 1 |
| Meert, AP | 1 |
| Dhalluin, X | 1 |
| Leclercq, N | 1 |
| Paesmans, M | 1 |
| Willems, L | 1 |
| Sculier, JP | 1 |
| Wadman, RI | 1 |
| Bosboom, WM | 1 |
| Iannaccone, ST | 1 |
| Vrancken, AF | 1 |
| Tsang, JP | 1 |
| Poon, WL | 1 |
| Luk, HM | 1 |
| Fung, CW | 1 |
| Ching, CK | 1 |
| Mak, CM | 1 |
| Lam, CW | 1 |
| Siu, TS | 1 |
| Tam, S | 1 |
| Wong, VC | 1 |
| Brownstone, E | 1 |
| Voigtländer, T | 1 |
| Baumhackl, U | 1 |
| Finsterer, J | 1 |
| Cruzado, D | 1 |
| Masserey-Spicher, V | 1 |
| Roux, L | 1 |
| Delavelle, J | 1 |
| Picard, F | 1 |
| Haenggeli, CA | 1 |
| Veggiotti, P | 1 |
| Termine, C | 1 |
| Granocchio, E | 1 |
| Bova, S | 1 |
| Papalia, G | 1 |
| Lanzi, G | 1 |
| Errguig, L | 1 |
| Benomar, A | 1 |
| Messouak, W | 1 |
| Regragui, W | 1 |
| Benabdejlil, M | 1 |
| Yahyaoui, M | 1 |
| Chkili, T | 1 |
| Alderfer, BS | 1 |
| Allen, MH | 1 |
| Valente, KD | 1 |
| Freitas, A | 1 |
| Fiore, LA | 1 |
| Kim, CA | 1 |
| Hofer, A | 1 |
| Fleischhacker, WW | 1 |
| Hummer, M | 1 |
| Sokolski, KN | 1 |
| Denson, TF | 1 |
| Cerna, D | 1 |
| Scott, T | 1 |
| Sproull, M | 1 |
| Burgan, WE | 1 |
| Cerra, MA | 1 |
| Fine, H | 1 |
| Sugai, F | 1 |
| Yamamoto, Y | 1 |
| Miyaguchi, K | 1 |
| Zhou, Z | 1 |
| Sumi, H | 1 |
| Hamasaki, T | 1 |
| Goto, M | 1 |
| Sakoda, S | 1 |
| Oertl, A | 1 |
| Relja, B | 1 |
| Makarevic, J | 1 |
| Weich, E | 1 |
| Höfler, S | 1 |
| Jones, J | 1 |
| Jonas, D | 1 |
| Bratzke, H | 1 |
| Baer, PC | 1 |
| Blaheta, RA | 1 |
| Annicotte, JS | 1 |
| Iankova, I | 1 |
| Miard, S | 1 |
| Fritz, V | 1 |
| Sarruf, D | 1 |
| Abella, A | 1 |
| Berthe, ML | 1 |
| Noël, D | 1 |
| Pillon, A | 1 |
| Iborra, F | 1 |
| Dubus, P | 1 |
| Maudelonde, T | 1 |
| Culine, S | 1 |
| Fajas, L | 1 |
| Ances, BM | 1 |
| Letendre, S | 1 |
| Buzzell, M | 1 |
| Marquie-Beck, J | 1 |
| Lazaretto, D | 1 |
| Marcotte, TD | 1 |
| Grant, I | 1 |
| Ellis, RJ | 1 |
| Nakamura, M | 1 |
| Salisbury, DF | 1 |
| Hirayasu, Y | 1 |
| Bouix, S | 1 |
| Pohl, KM | 1 |
| Yoshida, T | 1 |
| Koo, MS | 1 |
| Shenton, ME | 1 |
| McCarley, RW | 1 |
| Parsonage, B | 1 |
| Hinds, M | 1 |
| Post, RM | 1 |
| Weiss, SR | 1 |
| Prats, JM | 1 |
| Garaizar, C | 1 |
| García-Nieto, ML | 1 |
| Madoz, P | 1 |
| Diehl, B | 1 |
| Wyllie, E | 1 |
| Rothner, AD | 1 |
| Bingaman, W | 1 |
| Lehesjoki, AE | 1 |
| Koskiniemi, M | 1 |
| Taubøll, E | 1 |
| Isojärvi, JI | 1 |
| Harbo, HF | 1 |
| Pakarinen, AJ | 1 |
| Gjerstad, L | 1 |
| Caneppele, S | 1 |
| Mazereeuw-Hautier, J | 1 |
| Bonafé, JL | 1 |
| Wirrell, E | 1 |
| Camfield, C | 1 |
| Camfield, P | 1 |
| Dooley, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Integrated European Platform to Conduct Translational Studies in Myelodysplastic Syndromes Based on the EuroBloodNet Infrastructure[NCT04174547] | 8,670 participants (Anticipated) | Observational | 2019-09-30 | Recruiting | |||
| A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies[NCT00215605] | Phase 1 | 85 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| Phase I Study of Tipifarnib (R115777) and Sorafenib (BAY 43-9006) in Patients With Biopsiable Advanced Cancers[NCT00244972] | Phase 1 | 74 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma[NCT00121680] | Phase 1 | 115 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Multi-Arm Complete Phase 1 Trial of Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor[NCT00495872] | Phase 1 | 204 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| An Open-label, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Doxorubicin in Combination With Radiotherapy, Temozolomide and Valproic Acid in Patients With Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG)[NCT02758366] | Phase 2 | 21 participants (Actual) | Interventional | 2016-02-29 | Terminated (stopped due to Study was terminated due to high heterogeneity of enrolled patients) | ||
| A Randomized, Double-Blind, Placebo-Controlled Sequential Clinical Trial of Sodium Valproate in ALS[NCT00136110] | Phase 3 | 165 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| A Phase II Study Assessing the Activity of Valproate Acid Plus Doxorubicin in Refractory or Recurrent Malignant Mesothelioma[NCT00634205] | Phase 2 | 45 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for valproic acid and Disease Exacerbation
| Article | Year |
|---|---|
More is better: combination therapies for myelodysplastic syndromes.
Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Decitabine; Disease Progre | 2015 |
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
Topics: Antibodies, Monoclonal; Azacitidine; Azetidines; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small | 2016 |
Rapidly progressive Kaposi's Sarcoma in an Iraqi boy received Valproic acid: a case report and review of literature.
Topics: Anticonvulsants; Child; Disease Progression; Fatal Outcome; Humans; Immunosuppressive Agents; Iraq; | 2016 |
Drug treatment for spinal muscular atrophy types II and III.
Topics: Acetylcarnitine; Adolescent; Amines; Child; Child, Preschool; Creatine; Cyclohexanecarboxylic Acids; | 2012 |
Treatment of agitation in bipolar disorder across the life cycle.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Age of Onset; Anticonvulsants; Antipsychotic Agents; | 2003 |
A study of EEG and epilepsy profile in Wolf-Hirschhorn syndrome and considerations regarding its correlation with other chromosomal disorders.
Topics: Angelman Syndrome; Anticonvulsants; Child; Chromosome Deletion; Chromosome Disorders; Chromosomes, H | 2003 |
A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures.
Topics: Affect; Amygdala; Animals; Anticonvulsants; Bipolar Disorder; Carbamazepine; Disease Progression; Dr | 1996 |
Clinical features and genetics of progressive myoclonus epilepsy of the Univerricht-Lundborg type.
Topics: Adolescent; Adult; Age Distribution; Anticonvulsants; Child; Child, Preschool; Disease Progression; | 1998 |
5 trials available for valproic acid and Disease Exacerbation
| Article | Year |
|---|---|
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc | 2013 |
A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Alkylating; Bone Marrow; Brain Neoplasms; Chemoradi | 2015 |
Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis.
Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Enzyme Inhibit | 2009 |
Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Diseas | 2011 |
Long-term neuropsychological follow-up and nosological considerations in five patients with continuous spikes and waves during slow sleep.
Topics: Adrenocorticotropic Hormone; Anti-Anxiety Agents; Anticonvulsants; Benzodiazepines; Child; Child, Pr | 2002 |
46 other studies available for valproic acid and Disease Exacerbation
| Article | Year |
|---|---|
Cell necrosis, intrinsic apoptosis and senescence contribute to the progression of exencephaly to anencephaly in a mice model of congenital chranioschisis.
Topics: Amniotic Fluid; Anencephaly; Animals; Apoptosis; Brain; Caspase 3; Caspase 9; Cellular Senescence; C | 2019 |
Three-year longitudinal cognitive functioning in patients recently diagnosed with bipolar disorder.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Case-Control Studies; C | 2020 |
Sex difference in the progression of manic symptoms during acute hospitalization: A prospective pilot study.
Topics: Adult; Aggression; Antimanic Agents; Bipolar Disorder; Disease Progression; Female; Follow-Up Studie | 2020 |
Association of Valproic Acid Use, a Potent Histone Deacetylase Inhibitor, and Melanoma Risk.
Topics: Adult; Aged; Disease Progression; Female; Follow-Up Studies; Histone Deacetylase Inhibitors; Humans; | 2020 |
Vanishing White Matter Hyperintensities in CADASIL: A Case Report with Insight into Disease Mechanisms.
Topics: Antimanic Agents; Bipolar Disorder; Brain; CADASIL; Disease Progression; Drug Substitution; Female; | 2020 |
Long-term prognosis of childhood absence epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Disease Progression; Epilepsy, Absence; Ethosuximide; Female; Hu | 2019 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; | 2017 |
Gait instability in valproate-treated patients: Call to measure ammonia levels.
Topics: Accidental Falls; Adult; Ammonia; Anticonvulsants; Disease Progression; Epilepsy, Frontal Lobe; Fema | 2017 |
Magnesium valproate ameliorates type 1 diabetes and cardiomyopathy in diabetic rats through estrogen receptors.
Topics: Animals; Cardiomegaly; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetic Cardiomy | 2018 |
Metabolomics profiling of steatosis progression in HepaRG
Topics: Biomarkers; Chemical and Drug Induced Liver Injury; Chromatography, Liquid; Disease Progression; Hep | 2018 |
Occipital epilepsy versus progressive myoclonic epilepsy in a patient with continuous occipital spikes and photosensitivity in electroencephalogram: A case report.
Topics: Anticonvulsants; Atrophy; Cerebral Cortex; Diagnosis, Differential; Disease Progression; Electroence | 2018 |
Childhood Absence Epilepsy evolving to Eyelid Myoclonia with Absence Epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Disease Progression; Electroencephalography; E | 2018 |
Valproic acid suppresses Warburg effect and tumor progression in neuroblastoma.
Topics: Aerobiosis; Animals; Antineoplastic Agents; Child; Cytokines; Disease Progression; Down-Regulation; | 2019 |
Novel SCN2A mutation in a family associated with juvenile-onset myoclonus: Case report.
Topics: Adult; Anticonvulsants; Ataxia; Carbamazepine; Disease Progression; Drug Resistant Epilepsy; Electro | 2019 |
[The syndrome of malignant migrating partial seizures in infancy or Coppola-Dulac syndrome (19 cases)].
Topics: Anticonvulsants; Disease Progression; Electroencephalography; Epilepsies, Partial; Female; Follow-Up | 2013 |
Blood levels of cytokines in children with idiopathic partial and generalized epilepsy.
Topics: Anticonvulsants; Chi-Square Distribution; Child; Cytokines; Disease Progression; Electroencephalogra | 2013 |
Epilepsy and brain injury: a case report of a dramatic neuropsychiatric vicious circle.
Topics: Accidents, Traffic; Aggression; Amines; Anterior Temporal Lobectomy; Anticonvulsants; Brain Injuries | 2013 |
[Benign myoclonic epilepsy in infancy: natural history and behavioral and cognitive outcome].
Topics: Anticonvulsants; Attention Deficit Disorder with Hyperactivity; Child Behavior Disorders; Cognition | 2014 |
Cognitive change in the year after a first manic episode: association between clinical outcome and cognitive performance early in the course of bipolar I disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Bipolar Disorder; British Columbia; Cognition Disorders; Di | 2014 |
Sodium valproate-aggravated psoriasiform eruption.
Topics: Adolescent; Anticonvulsants; Disease Progression; Drug Eruptions; Humans; Male; Psoriasis; Valproic | 2014 |
Decreased right hippocampal volumes and neuroprogression markers in adolescents with bipolar disorder.
Topics: Adolescent; Antidepressive Agents; Bipolar Disorder; Brain-Derived Neurotrophic Factor; Disease Prog | 2015 |
Epileptogenesis and epileptic maturation in phosphorylation site-specific SNAP-25 mutant mice.
Topics: Animals; Anticonvulsants; Anxiety; Blotting, Western; Brain; Disease Progression; Electrocorticograp | 2015 |
Ketogenic diet prevents epileptogenesis and disease progression in adult mice and rats.
Topics: Adenosine; Animals; Anticonvulsants; Diet, Ketogenic; Disease Models, Animal; Disease Progression; D | 2015 |
Successful treatment of Sydenham's chorea with intravenous immunoglobulin.
Topics: Anti-Bacterial Agents; Child; Chorea; Disease Progression; Female; Haloperidol; Humans; Immunoglobul | 2016 |
Considering Valproate as a Risk Factor for Rapid Exacerbation of Complex Movement Disorder in Progressed Stages of Late-Infantile CLN2 Disease.
Topics: Anticonvulsants; Child; Child, Preschool; Consciousness Disorders; Creatine Kinase; Deprescriptions; | 2016 |
Clinical alertness to valproic acid-induced hyperammonemia--two case reports.
Topics: Adult; Antimanic Agents; Brain Diseases, Metabolic; Disease Progression; Electroencephalography; Fem | 2010 |
Valproate ameliorates the survival and the motor performance in a transgenic mouse model of Huntington's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; | 2009 |
Reversible rapidly progressive dementia with parkinsonism induced by valproate in a patient with systemic lupus erythematosus.
Topics: Aged; Anticonvulsants; Dementia; Diagnosis, Differential; Disease Progression; Epilepsy, Generalized | 2010 |
Arginase deficiency with new phenotype and a novel mutation: contemporary summary.
Topics: Anticonvulsants; Arginase; Base Sequence; Carcinoma, Hepatocellular; Cerebral Palsy; Codon, Nonsense | 2012 |
Epilepsy in adult X-linked adrenoleucodystrophy due to the deletion c.1415-1416delAG in exon 5 of the ABCD1-gene.
Topics: Adrenoleukodystrophy; Anticonvulsants; ATP Binding Cassette Transporter, Subfamily D, Member 1; ATP- | 2013 |
Early onset and rapidly progressive subacute sclerosing panencephalitis after congenital measles infection.
Topics: Age of Onset; Anticonvulsants; Antiviral Agents; Disease Progression; Electroencephalography; Fatal | 2002 |
[Favorable course of Lance-Adams postanoxic action myoclonus].
Topics: Anticonvulsants; Disease Progression; Electroencephalography; Electrophysiology; Humans; Hypoxia, Br | 2003 |
Worsening of psychosis after replacement of adjunctive valproate with topiramate in a schizophrenia patient.
Topics: Adult; Anticonvulsants; Clozapine; Disease Progression; Dose-Response Relationship, Drug; Drug Thera | 2003 |
Exacerbation of mania secondary to right temporal lobe astrocytoma in a bipolar patient previously stabilized on valproate.
Topics: Anticonvulsants; Antimanic Agents; Astrocytoma; Bipolar Disorder; Brain Neoplasms; Disease Progressi | 2003 |
Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid.
Topics: Acetylation; Animals; Brain Neoplasms; Cell Death; Cell Proliferation; Disease Progression; DNA Repa | 2005 |
Benefit of valproic acid in suppressing disease progression of ALS model mice.
Topics: Age of Onset; Amyotrophic Lateral Sclerosis; Animals; Cell Count; Cell Death; Dicarboxylic Acids; Di | 2004 |
Altered expression of beta1 integrins in renal carcinoma cell lines exposed to the differentiation inducer valproic acid.
Topics: Carcinoma, Renal Cell; Cell Adhesion; Cell Differentiation; Cell Line, Tumor; Cells, Cultured; Disea | 2006 |
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer.
Topics: Animals; Cadherins; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progressio | 2006 |
Valproic acid does not affect markers of human immunodeficiency virus disease progression.
Topics: Adult; Anticonvulsants; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Disease Progre | 2006 |
Neocortical gray matter volume in first-episode schizophrenia and first-episode affective psychosis: a cross-sectional and longitudinal MRI study.
Topics: Adolescent; Adult; Affective Disorders, Psychotic; Algorithms; Antimanic Agents; Antipsychotic Agent | 2007 |
Growing evidence to support early intervention in early onset bipolar disorder?
Topics: Adolescent; Age of Onset; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Child; Child, Pre | 2008 |
Antiepileptic drugs and atypical evolution of idiopathic partial epilepsy.
Topics: Anticonvulsants; Carbamazepine; Cerebral Cortex; Child; Child, Preschool; Disease Progression; Elect | 1998 |
Worsening seizures after surgery for focal epilepsy due to emergence of primary generalized epilepsy.
Topics: Adolescent; Anticonvulsants; Disease Progression; Electroencephalography; Epilepsies, Partial; Epile | 1998 |
Long-term valproate treatment induces changes in ovarian morphology and serum sex steroid hormone levels in female Wistar rats.
Topics: Administration, Oral; Animals; Anticonvulsants; Disease Models, Animal; Disease Progression; Dose-Re | 1999 |
[Sodium valproate-induced kinky hair].
Topics: Child; Diagnosis, Differential; Disease Progression; Female; GABA Agents; Humans; Menkes Kinky Hair | 2001 |
Prognostic significance of failure of the initial antiepileptic drug in children with absence epilepsy.
Topics: Adolescent; Age Factors; Anticonvulsants; Child; Disease Progression; Electroencephalography; Epilep | 2001 |